Pita-Fernandez Salvador, Valdes-Cañedo Francisco, Pertega-Diaz Sonia, Seoane-Pillado Maria Teresa, Seijo-Bestilleiro Rocio
Clinical Epidemiology and Biostatistics Unit, University Hospital Complex of A Coruña, Hotel de Pacientes 7a Planta, As Xubias, A Coruña, Spain.
BMC Cancer. 2009 Aug 22;9:294. doi: 10.1186/1471-2407-9-294.
Different publications show an increased incidence of neoplasms in renal transplant patients. The objective of this study is to determine the incidence of cancer in the recipients of renal transplants performed in the A Coruña Hospital (Spain) during the period 1981-2007.
METHODS/DESIGN: During the study period 1967 kidney transplants were performed, corresponding to 1710 patients. Patients with neoplasms prior to the transplant will be excluded (n = 38). A follow-up study was carried out in order to estimate cancer incidence after transplantation.For each patient, information included donor and recipient characteristics, patients and graft survival and cancer incidence after transplantation. Incident cancer is considered as new cases of cancer after the transplant with anatomopathological confirmation. Their location will be classified according to the ICD-9.The analysis will be calculated using the indirect standardisation method. Age-adjusted cancer incidence rates in the Spanish general population will be obtained from the Carlos III Health Institute, the National Epidemiology Centre of the Ministry of Science and Technology. Crude first, second and third-year post-transplantation cancer incidence rates will be calculated for male and female recipients. The number of cases of cancer at each site will be calculated from data in the clinical records. The expected number of cancers will be calculated from data supplied by the Carlos III Health Institute. For each tumour location we will estimate the standardized incidence ratios (SIRs), using sex-specific cancer incidence rates, by dividing the incidence rate for the transplant patients by the rate of the general population. The 95% confidence intervals of the SIRs and their associated p-values will be calculated by assuming that the observed cancers follow a Poisson distribution. Stratified analysis will be performed to examine the variation in the SIRs with sex and length of follow-up.Competing risk survival analysis methods will be applied to estimate the cumulative incidence of cancer and to identify variables associated to its occurrence.
Information about cancer incidence in kidney transplant patients could be useful to adapt the guidelines on post-kidney transplant follow-up on tumour screening, and evaluate the impact of intervention measures for the prevention of cancer in these patients.
不同的出版物显示肾移植患者肿瘤发病率有所增加。本研究的目的是确定1981年至2007年期间在西班牙拉科鲁尼亚医院进行肾移植的受者中癌症的发病率。
方法/设计:在研究期间共进行了1967例肾移植手术,涉及1710名患者。移植前患有肿瘤的患者将被排除(n = 38)。开展了一项随访研究,以估计移植后的癌症发病率。对于每位患者,收集的信息包括供体和受体特征、患者及移植物存活情况以及移植后的癌症发病率。确诊癌症被视为移植后经解剖病理学确认的癌症新病例。其位置将根据国际疾病分类第九版(ICD - 9)进行分类。分析将采用间接标准化方法进行计算。西班牙普通人群的年龄调整癌症发病率将从卡洛斯三世卫生研究所(科学与技术部国家流行病学中心)获取。将计算男性和女性受者移植后第一年、第二年和第三年的粗癌症发病率。每个部位的癌症病例数将根据临床记录中的数据计算得出。预期癌症病例数将根据卡洛斯三世卫生研究所提供的数据计算得出。对于每个肿瘤部位,我们将使用特定性别的癌症发病率,通过将移植患者的发病率除以普通人群的发病率来估计标准化发病率(SIRs)。SIRs的95%置信区间及其相关的p值将通过假设观察到的癌症遵循泊松分布来计算。将进行分层分析,以研究SIRs随性别和随访时间的变化。将应用竞争风险生存分析方法来估计癌症的累积发病率,并确定与其发生相关的变量。
肾移植患者癌症发病率的信息可能有助于调整肾移植后肿瘤筛查随访指南,并评估这些患者预防癌症干预措施的效果。